Orphazyme ApS: Former Operations in Orphan Protein-Misfolding Diseases
Orphazyme A/S, a biopharmaceutical company originally headquartered in Copenhagen, Denmark, was dedicated to the discovery and development of novel treatments for a family of serious genetic disorders, specifically orphan protein-misfolding diseases and lysosomal storage diseases. Its operational focus was entirely on its proprietary small-molecule therapeutic platform. The company's core mission centered on restoring cellular balance through the mobilization of a group of stress-response proteins known as Heat-Shock Proteins (HSPs).
Operational Focus and Mechanism of Action
Continue…The central scientific and operational pillar of Orphazyme was the development of therapies that acted as Heat-Shock Protein (HSP) Amplifiers. In healthy cells, HSPs function as molecular chaperones, playing a crucial role in maintaining cellular homeostasis by managing the proper folding, trafficking, and clearance of proteins. In diseases characterized by protein-misfolding and aggregation, such as many lysosomal storage disorders and neurodegenerative conditions, the cell's natural HSP response is often impaired or overwhelmed.
Orphazyme's lead product candidate, arimoclomol, was an orally-administered, first-in-class investigational drug designed to enhance the production of these protective HSPs. By amplifying the cell???s natural stress response, the compound aimed to:
* Rescue defective and misfolded proteins.
* Improve the function of lysosomes, which are critical cellular organelles for waste disposal that malfunction in lysosomal storage diseases.
* Prevent the aggregation of toxic proteins.
This unique therapeutic approach was intended to slow down or halt disease progression across a range of debilitating rare disorders.
Products and Services (Investigational Pipeline)
As a late-stage biopharmaceutical company, Orphazyme???s primary "products" were its investigational drug candidates in clinical development. The company did not offer commercial products or traditional services, but instead focused on research, clinical trials, and compassionate use programs for its lead compound.
1. Arimoclomol
Arimoclomol was the company???s flagship and sole clinical-stage asset, pursued across multiple rare disease indications.
Niemann-Pick Disease Type C (NPC): This was Orphazyme's lead indication for arimoclomol. NPC is a rare, progressive, neurodegenerative lysosomal storage disorder, characterized by the inability to transport cholesterol and lipids inside cells, leading to their abnormal accumulation in tissues, including the brain. Arimoclomol was studied in a pivotal Phase 2/3 clinical trial and had received multiple regulatory designations for NPC, including:
- Orphan Drug Designation (ODD) in the US and EU.
- Fast-Track Designation (FTD) from the U.S. Food and Drug Administration (FDA).
- Breakthrough Therapy Designation (BTD) from the FDA.
- Rare Pediatric Disease Designation (RPDD) from the FDA.
- Early Access Programs (EAPs): Prior to its sale, Orphazyme provided arimoclomol to eligible NPC patients in certain countries, such as France and Germany, through Early Access Programs, which constituted the company's only source of limited, non-commercial revenue.
Amyotrophic Lateral Sclerosis (ALS): A Phase 3 clinical trial for arimoclomol in ALS (a fatal neurodegenerative disease affecting motor neurons) was completed, using a measure called the Combined Assessment of Function and Survival (CAFS) as a primary endpoint.
Sporadic Inclusion Body Myositis (sIBM): Arimoclomol was also investigated for the treatment of sIBM, a debilitating, progressive muscle disorder that causes muscle weakness and wasting. This program had advanced to a Phase 2/3 trial.
Gaucher Disease: The compound was also in clinical development for Gaucher disease, another lysosomal storage disorder.
2. Other Research Activities
Beyond arimoclomol, the company???s research and development services were focused on identifying new HSP amplifier compounds and exploring their potential therapeutic use in other protein-misfolding disorders.
Current Corporate Status
It is critical to note that the operational existence of Orphazyme A/S has fundamentally changed. Following an in-court restructuring process in Denmark, the company entered into an agreement in May 2022 to sell substantially all of its assets and business activities, including the lead compound arimoclomol and its related programs, to KemPharm, Inc.
As a direct result of this transaction and completion of the sale, Orphazyme A/S ceased to have any ongoing operational business activities related to drug discovery, development, or commercialization. The original products and services???the drug candidate arimoclomol and its associated development programs???were transferred to the acquiring entity. The company???s current activities are those residual corporate functions necessary for a non-operational entity following a major asset sale. Its primary original function as a late-stage biopharmaceutical developer of HSP amplifiers for rare diseases is now defunct.
